Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yuki, Fujimoto"'
Autor:
YUKI FUJIMOTO, TADASHI NAMISAKI, SOICHI TAKEDA, KOJI MURATA, MASAHIDE ENOMOTO, HIROAKI TAKAYA, YUKI TSUJI, YUKIHISA FUJINAGA, YASUHIKO SAWADA, NORIHISA NISHIMURA, KOH KITAGAWA, KOSUKE KAJI, TAKASHI INOUE, HIDETO KAWARATANI, KEI MORIYA, TAKEMI AKAHANE, AKIRA MITORO, HITOSHI YOSHIJI
Publikováno v:
Anticancer Research. 42:4895-4905
To identify predictors of severe adverse events (≥grade 3) in patients with advanced hepatocellular carcinoma treated with lenvatinib.Of 41 patients, 25 and 16 were stratified into the severe and non-severe adverse events groups, respectively. Of t
Autor:
NOBUYUKI YORIOKA, TADASHI NAMISAKI, AKIHIKO SHIBAMOTO, JUNYA SUZUKI, TAKAHIRO KUBO, SATOSHI IWAI, FUMIMASA TOMOOKA, MISAKO TANAKA, SOICHI TAKEDA, YUKI FUJIMOTO, MASAHIDE ENOMOTO, KOJI MUARATA, TAKASHI INOUE, YUKI TSUJI, YUKIHISA FUJINAGA, NORIHISA NISHIMURA, KOH KITAGAWA, HIROAKI TAKAYA, KOSUKE KAJI, HIDETO KAWARATANI, TAKEMI AKAHANE, AKIRA MITORO, MASAHARU YAMAZAKI, HITOSHI YOSHIJI
Publikováno v:
In Vivo
Background/Aim: The management of refractory ascites is critical for the treatment of patients with decompensated cirrhosis. This study aimed to evaluate the feasibility and safety of cell-free and concentrated ascites reinfusion therapy (CART) in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bff0ca800add24948735322d838e2b6
https://europepmc.org/articles/PMC10188040/
https://europepmc.org/articles/PMC10188040/
Autor:
SOICHI TAKEDA, TADASHI NAMISAKI, YUKI TSUJI, YUKI FUJIMOTO, KOJI MURATA, MASAHIDE ENOMOTO, YUKIHISA FUJINAGA, NORIHISA NISHIMURA, KOH KITAGAWA, HIROAKI TAKAYA, KOSUKE KAJI, TAKASHI INOUE, HIDETO KAWARATANI, TAKEMI AKAHANE, AKIRA MITORO, HITOSHI YOSHIJI
Publikováno v:
Anticancer research. 42(11)
The current study evaluated the efficacy and toxicity of atezolizumab plus bevacizumab in patients with advanced-stage hepatocellular carcinoma in a real-world setting.This retrospective study enrolled 23 patients. The primary endpoint was progressio
Autor:
Kayoko Shoda, Hideaki Bando, Takashi Kojima, Tetsuro Sasada, Itaru Endo, Satoshi Wada, Kenichi Kohashi, Kazuto Nosaka, Toshiaki Yoshikawa, Yasuhiro Shimizu, Yuki Fujimoto, Tetsuya Nakatsura, Shoichi Mizuno
Publikováno v:
Cancer Science
Heat shock protein 105 (HSP105) is overexpressed in many cancers, including colorectal cancer (CRC) and esophageal cancer (EC). We carried out a phase I clinical trial of HLA‐A24‐ and HLA‐A2‐restricted HSP105 peptide vaccines in patients with
Autor:
Yusuke Baba, Yuki Ito, Masao Matsuoka, Akari Kuwano, Aina Nishigaki, Shikiko Ueno, Kazutaka Oda, Yuki Fujimoto, Yutaka Okuno, Yuka Nishimura, Natsumi Michiwaki, Shota Uchino, Hirofumi Jono, Ayami Yamaguchi, Yawara Kawano, Kayo Kurogi, Yumi Shimomura, Hideyuki Saito, Nao Gunda
Publikováno v:
Cancers
Cancers, Vol 13, Iss 5674, p 5674 (2021)
Volume 13
Issue 22
Cancers, Vol 13, Iss 5674, p 5674 (2021)
Volume 13
Issue 22
(1) Background: multiple myeloma patients have benefited from bortezomib therapy, though it has often been discontinued owing to diarrhea. The objective of this study was to verify serum bortezomib concentration in the emergence of diarrhea. (2) Meth
Autor:
Tetsuro Sasada, Erika Yada, Satoshi Wada, Shintaro Yoshida, Junya Ohtake, Yuki Fujimoto, Hidemi Uchiyama
Publikováno v:
Immunotherapy. 8(11)
Cancer immunotherapy has attracted attention worldwide owing to the recent development of immune checkpoint inhibitors. However, these therapies have shown limited efficacy, and further advancements are needed before these modalities can progress to
Autor:
Yuki Fujimoto, Satoshi Wada, Shoichi Mizuno, Itaru Endo, Tetsuro Sasada, Toshiaki Yoshikawa, Yasuhiro Shimizu, Kojima Takashi, Kayoko Shoda, Kenichi Kohashi, Kazuto Nosaka, Hideaki Bando, Tetsuya Nakatsura
Publikováno v:
Cancer Immunology Research. 7:A017-A017
Purpose: Heat shock protein 105 (HSP105) is overexpressed in a variety of human cancers, including colorectal cancer (CRC) and esophageal cancer (EC). We identified HLA-A24 or A2-restricted HSP105 peptides that can induce HSP105 peptide-specific cyto